(Q89948768)

English

Hypomethylating agents in combination with histone deacetylase inhibitors in higher risk myelodysplastic syndromes: Is there a light at the end of the tunnel?

scientific article published on 17 January 2017

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28094843%20AND%20SRC:MED&resulttype=core&format=json

10 April 2020

0 references

Hypomethylating agents in combination with histone deacetylase inhibitors in higher risk myelodysplastic syndromes: Is there a light at the end of the tunnel? (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28094843%20AND%20SRC:MED&resulttype=core&format=json

10 April 2020

author name string

Maximilian Stahl

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28094843%20AND%20SRC:MED&resulttype=core&format=json

10 April 2020

Amer M Zeidan

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28094843%20AND%20SRC:MED&resulttype=core&format=json

10 April 2020

publication date

17 January 2017

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28094843%20AND%20SRC:MED&resulttype=core&format=json

10 April 2020

number of pages

4

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28094843%20AND%20SRC:MED&resulttype=core&format=json

10 April 2020

123

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28094843%20AND%20SRC:MED&resulttype=core&format=json

10 April 2020

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28094843%20AND%20SRC:MED&resulttype=core&format=json

10 April 2020

911-914

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28094843%20AND%20SRC:MED&resulttype=core&format=json

10 April 2020

Recent developments in myelodysplastic syndromes.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30532

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30532

7 January 2021

based on heuristic

inferred from DOI database lookup

The clinical use of DNA methyltransferase inhibitors in myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30532

7 January 2021

based on heuristic

inferred from DOI database lookup

Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30532

7 January 2021

based on heuristic

inferred from DOI database lookup

Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30532

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30532

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30532

7 January 2021

based on heuristic

inferred from DOI database lookup

Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30532

7 January 2021

based on heuristic

inferred from DOI database lookup

Survival trends in primary myelodysplastic syndromes: a comparative analysis of 1000 patients by year of diagnosis and treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30532

7 January 2021

based on heuristic

inferred from DOI database lookup

Beyond hypomethylating agents failure in patients with myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30532

7 January 2021

based on heuristic

inferred from DOI database lookup

Epigenetics in Cancer: A Hematological Perspective

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30532

7 January 2021

based on heuristic

inferred from DOI database lookup

Aberrant DNA methylation is a dominant mechanism in MDS progression to AML.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30532

7 January 2021

based on heuristic

inferred from DOI database lookup

DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30532

7 January 2021

based on heuristic

inferred from DOI database lookup

Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30532

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase 2 study of vorinostat in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30532

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30532

7 January 2021

based on heuristic

inferred from DOI database lookup

Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30532

7 January 2021

based on heuristic

inferred from DOI database lookup

Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30532

7 January 2021

based on heuristic

inferred from DOI database lookup

Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30532

7 January 2021

based on heuristic

inferred from DOI database lookup

Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30532

7 January 2021

based on heuristic

inferred from DOI database lookup

Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30532

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher-risk myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30532

7 January 2021

based on heuristic

inferred from DOI database lookup

Predicting response to epigenetic therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30532

7 January 2021

based on heuristic

inferred from DOI database lookup

HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30532

7 January 2021

based on heuristic

inferred from DOI database lookup

Predicting Response to Histone Deacetylase Inhibitors Using High-Throughput Genomics.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30532

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.30532

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28094843%20AND%20SRC:MED&resulttype=core&format=json

10 April 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28094843%20AND%20SRC:MED&resulttype=core&format=json

10 April 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q89948768&oldid=1957168022"